Desvenlafaxine
Sold as Exsira, Voloxin, Depven xl, Dexinor xr, Denlazyd, Desvenlafaxine zydus, Rediruno xr, Desfaxanim, Desvexalin
4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
Drag to rotate. Structure from PubChem CID 125017.
Background
Registration
- Applicants
- 7
- Registrations
- 18
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pfizer Laboratories (Pty) Ltd | Exsira | 50 mg, 100 mg | 410427, 420935 | S5 | None |
| Pharmacare limited û woodmead | Voloxin | 50mg, 100 mg | 520952, 520953 | S5 | None |
| Cipla Medpro (Pty) Ltd | Depven xl | 50, 100 | 530048, 530049 | S5 | None |
| Unicorn Pharmaceuticals (Pty) Ltd | Dexinor xr | 50, 100 | 560735, 560736 | S5 | None |
| Zydus Healthcare (Pty) LtdCertificate held by Zydus Healthcare SA (Pty) Ltd | Denlazyd, Desvenlafaxine zydus | 50/100 mg, 50, 100 | 570461, 570462, 570463.461, 570464.462 | S5 | PIPIL |
| Dr Reddyæs Laboratories (Pty) Ltd | Rediruno xr | 50, 100 | 570569, 570570 | S5 | None |
| Macleods Pharmaceuticals SA (Pty) Ltd | Desfaxanim, Desvexalin | 50 mg, 100 mg | 600005, 600006, 600007, 600008 | S5 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Exsira 100 MG EACH TABLET CONTAINS DESVENLAFAXINE SUCCINATE 100,0 mg | 100 mg | 41042741/1.2/0427 | Registered | S5 | None |
| Exsira 50 MG EACH TABLET CONTAINS DESVENLAFAXINE SUCCINATE 50,0 mg | 50 mg | 42093542/1.2/0935 | Registered | S5 | None |
| Voloxin 50mg EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 50,0 mg | 50mg | 52095252/1.2/0952 | Registered | S5 | None |
| Voloxin 100 MG EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 100,0 mg | 100 mg | 52095352/1.2/0953 | Registered | S5 | None |
| Depven 50 xl ECAH TABLET CONTAINS DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 50,0 mg | 50 | 53004853/1.2/0048 | Registered | S5 | None |
| Depven 100 xl ECAH TABLET CONTAINS DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 100,0 mg | 100 | 53004953/1.2/0049 | Registered | S5 | None |
| Dexinor 50 xr Each Tablet contains: Desvenlafaxine Benzoate equivalent to Desvenlafaxine 50,0 mg | 50 | 56073556/1.2/0735 | Registered | S5 | None |
| Dexinor 100 xr Each Tablet contains: Desvenlafaxine Benzoate equivalent to Desvenlafaxine 100,0 mg | 100 | 56073656/1.2/07360 | Registered | S5 | None |
| Denlazyd 50 Each Tablet contains: Desvenlafaxine succinate equivalent to Desvenlafaxine 50,0 mg | 50/100 mgExtended-release tablets | 57046157/1.2/0461Approved 6 May 2025 | Registered | S5 | PIPIL |
| Denlazyd 100 Each Tablet contains: Desvenlafaxine succinate equivalent to Desvenlafaxine 100 mg | 50/100 mgExtended-release tablets | 57046257/1.2/0462Approved 6 May 2025 | Registered | S5 | PIPIL |
| Desvenlafaxine 50 zydus Each Tablet contains: Desvenlafaxine succinate equivalent to Desvenlafaxine 50,0 mg | 50 | 570463.46157/1.2/0463.461 | Registered | S5 | None |
| Desvenlafaxine 100 zydus Each Tablet contains: Desvenlafaxine succinate equivalent to Desvenlafaxine 100,0 mg | 100 | 570464.46257/1.2/0464.462 | Registered | S5 | None |
| Rediruno 50 xr Each Tablet contains: Desvenlafaxine Benzoate equivalent to Desvenlafaxine 50,0 mg | 50 | 57056957/1.2/0569 | Registered | S5 | None |
| Rediruno 100 xr Each Tablet contains: Desvenlafaxine Benzoate equivalent to Desvenlafaxine 100,0 mg | 100 | 57057057/1.2/0570 | Registered | S5 | None |
| Desfaxanim 50 MG EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 50,0 mg | 50 mg | 60000560/1.2/0005 | Registered | S5 | None |
| Desfaxanim 100 MG EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 100,0 mg | 100 mg | 60000660/1.2/0006 | Registered | S5 | None |
| Desvexalin 50 MG EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 50,0 mg | 50 mg | 60000760/1.2/0007 | Registered | S5 | None |
| Desvexalin 100 MG EACH TABLET CONTAINS: DESVENLAFAXINE SUCCINATE EQUIVALENT TO DESVENLAFAXINE 100,0 mg | 100 mg | 60000860/1.2/0008 | Registered | S5 | None |
Regulatory status
Where S5 sits on the scale
Prescription-only, with tighter controls on repeats.
Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S5, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.
Consolidated Schedules listings for Desvenlafaxine succinate
S5: Desvenlafaxine
Consolidated Schedules 06 July 2026, line 9367
Pharmacological class: Psychoanaleptics (antidepressants). (class 1.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Denlazyd 50, Zydus Healthcare (Pty) Ltd is scheduled S5 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.